D.V. Pasynkov1-3, R.I. Fatykhov3,4, B.Sh. Bikbov5

1Republican Clinical Oncological Dispensary, Yoshkar-Ola

2Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

3Mari State University, Yoshkar-Ola

4Kazan State Medical University, Kazan

5Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Kazan

 Pasynkov Dmitry V. ― Cand. of Sci. (Med.), Associate Professor, Head of the Department of Radiation Diagnostics of Republican Clinical Oncological Dispensary; Head of the Department of Radiation Diagnostics and Oncology of the Mari State University; Assistant of the Department of Ultrasound Diagnostics of the Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia

22 Osipenko Str., Yoshkar-Ola, 424037, Russian Federation, e-mail:, SPIN-code (RSCI): 7264-3745, Author ID (Scopus): 57194777454, Researcher ID (WoS): HJH-2122-2023, ORCID ID: 0000-0003-1888-2307


Purpose ― to analyze the incidence of the additional malignancies as a possible cause of decreased survival in patients with renal cell carcinoma (RCC).

Material and methods. We included 1 110 RCC patients who were initially diagnosed from 2013 to 2022. In this sample we identified the patients who had additional malignancies (other than RCC) diagnosed starting 6 months before the RCC diagnosis and to the end of the 2022.

Results. The most common primary malignancies in both gender were: colorectal cancer (relative risk [RR]=2,78 [95% confidence interval: 1,82-4,26]), prostate cancer (RR=4,23 [2,56-9,45]), lung cancer (RR=2,64 [1,46-4,76]), breast cancer (RR=1,91 [0,91-4,00]), and stomach cancer (RR=2,87 [1,44-5,74]). In men the most common primary malignancies which risk was significantly higher than in general population were: colorectal cancer (RR=3,38 [1,82-6,26]), prostate cancer (RR=4,03 [2,10-7,72]), lung cancer (RR=2,15 [1,12-4,12]), stomach cancer (RR=2,71 [1,21-6,02]), and melanoma (RR=5,02 [1,30-20,17]). In women such malignancies were the following: colorectal cancer (RR=5,05 [2,81-9,08]), breast cancer (RR=2,34 [1,12-4,90]), endometrial cancer (RR=3,59 [1,35-9,56]), thyroid gland cancer (RR=5,61 [1,40-22,46]) and skin cancer (non-melanomic) (RR=7,96 [1,98-31,98]).

Conclusion. The additional malignancies during the 6,7 (median) years of follow-up develop in 6,31% RCC patients, and this risk is higher than the one in the general population. This phenomenon makes the RCC patients to be the risk group for other malignancies.

Key words: renal cell carcinoma, additional primary malignant tumors, relative risk, incidence rate.